A Case of Mitral Annular Disjunction Combined with Ventricular Arrhythmias

Tatyana N. Novikova¹, Veronika A. Basova¹, Larisa S. Evdokimova¹, Natalia A. Gnevasheva², Irina E. Itskovich¹, Vladimir I. Novikov¹, Sergey A. Sayganov¹, Vladislava A. Shcherbakova¹

¹ North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
² Institute of Emergency Medicine Nikiforov’s All-Russian Center for Emergency and Radiation Medicine of the Emergencies Ministry of Russia, Saint Petersburg, Russia

The article presents a clinical case of a combination of mitral valve prolapse (MVP), mitral annular disjunction (MAD), and ventricular arrhythmia. The presence of MAD worsens the prognosis in MVP and predisposes to life-threatening ventricular arrhythmias. In a 42-year-old patient, MAD was detected during echocardiography to determine the indications for surgical correction of mitral insufficiency in MVP. Severe myxomatous degeneration of the mitral valve leaflets, polysegmental prolapse, and typical auscultatory pattern (systolic click followed by systolic murmur in the second half of systole) were the indications for the targeted search for MAD. Multi-day (ECG) monitoring recorded nonsustained ventricular tachycardias and premature ventricular complexes (PVCs). Cardiac magnetic resonance imaging was performed for confirmation the diagnosis and searched for left ventricular myocardial fibrosis accompanying MAD. Finally, MAD was confirmed, but myocardial fibrotic changes were not detected. Owing to the absence of myocardial fibrosis, the patient was treated conservatively with a beta-adrenoblocker (25 mg/day slow-release metoprolol succinate) in combination with 25 mg/day allaforte. Repeated 24-h ECG monitoring did not detect ventricular tachycardias and nonsustained registered a significant decrease of number of PVCs. The patient is followed up prospectively due to high risk factors for fibrosis and worsening prognosis, which may require surgical correction of the existing disturbances and/or implantation of a cardioverter-defibrillator.

Keywords: mitral annular disjunction; mitral valve prolapse; nonsustained entrical tachycardia.

To cite this article:
Novikova TN, Basova VA, Evdokimova LS, Gnevasheva NA, Itskovich IE, Novikov VI, Sayganov SA, Shcherbakova VA. A case of mitral annular disjunction combined with ventricular arrhythmias. Cardiac Arrhythmias. 2022;2(2);41–50. DOI: https://doi.org/10.17816/cardar109160
Случай митральной аннулярной дизъюнкции в сочетании с желудочковыми нарушениями ритма

Т.Н. Новикова¹, В.А. Басова¹, Л.С. Евдокимова¹, Н.А. Гневашева², И.Э. Ицкович¹,
В.И. Новиков¹, С.А. Сайганов¹, В.А. Щербакова¹

¹ Северо-Западный государственный медицинский университет им. И.И. Мечникова Минздрава России, Санкт-Петербург, Россия
² Институт дополнительного профессионального образования «Экстремальная медицина» Всероссийского центра экстренной и радиационной медицины МЧС России имени А.М. Никифорова, Санкт-Петербург, Россия

В статье представлен клинический случай сочетания пролапса митрального клапана (ПМК), митральной аннулярной дизъюнкции (МАД) и желудочковых нарушений ритма. Наличие МАД ухудшает прогноз при ПМК и предрасполагает к жизнеугрожающим желудочковым аритмиям. У пациентки 42 лет МАД выявлена при эхокардиографическом обследовании, которое она проходила для определения показаний к хирургической коррекции митральной недостаточности на фоне ПМК. Выраженная миксоматозная дегенерация створок митрального клапана, полисегментарный пролапс, классическая аускультативная картина (систолический клик, следующий за ним систолический шум во второй половине систолы) стали основанием для прицельного поиска МАД. При многосуточном мониторировании электрокардиографических данных зарегистрированы неустойчивые желудочковые тахикардии, частая желудочковая экстрасистолия. Для подтверждения диагноза и поиска фиброза миокарда левого желудочка, аккомпанирующего МАД, выполнена магниторезонансная томография сердца. Наличие МАД подтверждено, фиброзные изменения миокарда не выявлены. В связи с отсутствием фиброза миокарда принято решение о консервативном лечении бета-адреноблокатором (метопролола сукиннат замедленного высвобождения в дозе 25 мг в сутки) в сочетании с аллафорте 25 мг в сутки. На фоне терапии при повторном суточном мониторировании ЭКГ не зарегистрированы неустойчивые желудочковые тахикардии, уменьшилось количество желудочковых экстрасистол. За пациенткой осуществляется проспективное наблюдение в связи с наличием факторов высокого риска появления фиброза и ухудшения прогноза, которые в свою очередь могут потребовать хирургической коррекции имеющейся патологии и/или имплантации кардиовертера-дефибриллятора.

Ключевые слова: митральная аннулярная дизъюнкция; пролапс митрального клапана; неустойчивая желудочковая тахикардия.

Как цитировать:
Новикова Т.Н., Басова В.А., Евдокимова Л.С., Гневашева Н.А., Ицкович И.Э., Новиков В.И., Сайганов С.А., Щербакова В.А. Случай митральной аннулярной дизъюнкции в сочетании с желудочковыми нарушениями ритма // Cardiac Arrhythmias. 2022. Т. 2, № 2. С. 41–50. DOI: https://doi.org/10.17816/cardar109160
BACKGROUND

Mitral valve prolapse (MVP) is a common pathology in the clinical practice of a cardiologist and therapist. In the adult population, the prevalence of MVP reaches 2%–3% [1, 2], with favorable prognosis in most cases [3–6]. According to Nishimura et al., the 8-year survival rate of patients with MVP is 88% and is not significant different compared with the main parameters of the control group [3]. However, the disease course may be complicated by malignant ventricular arrhythmias and sudden death in some young and middle-aged patients [7–9]. The risk stratification criteria for adverse ventricular arrhythmias in MVP are under development. The prolapse of both mitral valve leaflets, its degree of severity, papillary muscles fibrosis, and mitral annular disjunction (MAD) are associated with the risk of ventricular arrhythmias [8–12].

MAD is a structural abnormality defined as separation (disconnection) or absence of the direct transition of the left atrial (LA) myocardium into the left ventricular (LV) myocardium in the area of the mitral valve annulus and partial replacement of the LV myocardium under the mitral valve annulus with fibrous tissue [2]. MAD is a common finding in patients with MVP [2]. Its detection varies from 42% to 98% and correlates with the degree of prolapse severity [2, 13]. MAD was first described in combination with MVP in the 1980s [14]. The clinical significance of this structural abnormality remained unclear, and the problem was not studied until 2005. Eriksson et al. observed MAD with transesophageal echocardiography (EchoCG) and described direct surgical cardiac examination in this patients during surgery for severe mitral insufficiency resulting from myxomatous degeneration of the mitral valve leaflets in 2005 [13]. They demonstrated a direct correlation between the severity of MAD, number of altered leaflet segments, and severity of MVP. Moreover, MAD plays an important role in arrhythmogenesis [2, 15]. The physician’s task is to promptly recognize this abnormality, establish its correlation with arrhythmias, prescribe antiarrhythmic therapy, and dynamically monitor the patient to determine indications for cardioverter-defibrillator implantation and surgical correction of the existing disturbances.

CLINICAL CASE

Patient I., 42 years old, came to our clinic to decide on indications for surgical treatment of mitral insufficiency. On admission, complaints included frequent heart palpitations for 6 months. The patient was treated in the outpatient clinic at the place of residence. The examination revealed MVP with moderate-to-severe mitral regurgitation. Low-dose therapy with beta-adrenoblockers (2.5 mg/day bisoprolol) was ineffective. When trying to increase the drug dose, the patient became hypotensive, and the resting heart rate decreased to 45 bpm during the daytime.

Family history is not burdened. The patient gave birth to three healthy children.

On physical examination, the condition was assessed as satisfactory. The color of the skin and visible mucous membranes were normal. No peripheral edemas were observed. The patient had a normal build. The body mass index was 21.30 kg/m². Arterial pressure was 115/70 mm Hg. The resting heart rate and pulse were 65 bpm. Percussion revealed a slight left shift of the left heart border. On auscultation, the sonority of the first and second sounds was unchanged, and no additional sounds were detected. A systolic click was heard in the middle systole, followed by a systolic murmur at Botkin–Erb’s point with irradiation toward the aorta and apex. There were pulmonary sound on percussion and vesicular breathing on auscultation. On palpation, the abdomen was soft and painless, and the liver was not enlarged. The six-minute walk test was 560 m.

EchoCG was performed using modern technologies of three-dimensional image reconstruction and Mitral Valve Quantification model on Vivid-9 ultrasound device. The results showed that mitral regurgitation was mild [16]. The effective regurgitation orifice area was 0.18 cm², and the regurgitation volume was 20 mL. Both mitral valve leaflets were myxomatous, thickened, and prolapsed up to 8 mm into the LA cavity (Fig. 1–3). The prolapse was

Fig. 1. Parasternal long-axis view of the left ventricle. Systole. White arrows indicate elongated and thickened mitral valve leaflets prolapsing into the left atrial cavity. The black arrow indicates the disjunction area

Fig. 2. Parasternal long-axis view of the left ventricle. Diastole. The elongated and thickened mitral valve leaflets (predominantly posterior) are visible. The black arrow indicates the disjunction area below the posterior mitral valve leaflet.
polysegmental (Fig. 4). Signs of MAD (absence of myocardial tissue up to 9 mm under the posterior mitral valve leaflet) were revealed (Fig. 1, 2).

LV was slightly dilated, and the end-diastolic volume (EDV) index was 68 mL/m². LV myocardial hypertrophy was revealed, and the myocardial mass index was 98/m². Systolic function was preserved, and ejection fraction (EF) was 68%. The calculated pulmonary artery pressure was not elevated.

Cardiac magnetic resonance imaging (CMR) was performed on a Signa Pioneer 3.0 T scanner (General Electric Healthcare, Chicago, IL, USA) using 16-channel and 32-channel body coils to verify the diagnosis. Scans were performed according to a standard protocol with late contrast enhancement 8–15 min after injection of gadolinium-based contrast agent at a dose of 0.02 mmol/kg (0.5 mmol/L gadodiamide). The following pulse sequences were used: Fiesta Cine (dynamic cine imaging), T1 double-inversion recovery (DIR), T2 DIR fat saturation, and delayed myocardial enhancement (MDE) performed with breath-holding in standard cardiac projections. Postprocessing image analysis was performed using the CardiacVX software package (General Electric Healthcare). The following parameters were assessed: EF of 47% (normal range, 58%–76%), stroke volume of 84 (normal range, 59–115) mL, EDV of 180 (normal range, 90–171) mL, end-systolic volume (ESV) of 96 (normal range, 25–62) mL, EDV index of 105 (normal range, 59–93) mL/m², ESV index of 56 (normal range, 16–34) mL/m², myocardial mass of 160 (normal range, 71–143) g, and LA bi-plane volume of 112 (normal range, 47–131) mL.

Despite the good comparability of EchoCG and CMR data in assessing EF and LV volumes, many studies have demonstrated the differences between these methods. The range of over- and underestimation of contractile function in CMR may reach 20% according to the Bland–Altman plots [17]. In addition, differences in EchoCG and CMR results are due to different counting techniques. Standardly, automatic or semiautomatic counting based on short axis LV images is used for CMR. In addition, measurement errors obtained with CMR may be due to insufficient spatial resolution and the effect of volume averaging associated with nonoptimal slice thickness, which is not always technically to be corrected. Moreover, arrhythmias contribute to inaccuracies in obtaining LV volumes and, accordingly, to errors in EF calculation. Based
on the difference in EF values (EchoCG showed normal EF values, whereas CMR showed decreased EF), the decision was to dynamically monitor the patient’s clinical condition, cardiac chamber size, and EF.

The distance from the base of the mitral valve fibrous annulus to the upper contour of the LV myocardium was measured on end-systolic cine images. The MAD extent at the level of the posterior and anterior mitral valve leaflets was measured along the three-chamber and long LV axis, respectively. The MAD extent was 11 mm and 5 mm under the posterior and anterior leaflets, respectively (Fig. 5, 6).

Additionally, a descending systolic motion of the posterior part of the mitral valve annulus with hyperkinetic contraction of the adjacent basal myocardium was observed (systolic curling). Myocardial thickening of the posterior wall and adjacent segments of the interventricular septum and lateral wall were assessed on short axis and three-chamber-axis LV images. The end-systolic myocardial thickness of basal inferior septal and inferolateral segments was 13 mm and that of the inferior basal segment was 15 mm (Fig. 7).

No reliable areas of late gadolinium enhancement (LGE) in the myocardium, corresponding to fibrous changes, were found. The patient was recommended for follow-up and dynamic CMR monitoring to exclude fibrotic structural changes in the long term and assess the risk of adverse ventricular arrhythmias.

Resting 12-lead ECG showed sinus rhythm, early repolarization syndrome, and single premature ventricular complexes (PVCs) (Fig. 8).

Multi-day ECG monitoring (154 h) was performed. Single monomorphic premature ventricular complexes (PVCs) (54,529 [8.5%]) and paired (1,078 [2.1%]) and runs of monomorphic nonsustained ventricular tachycardia of 3–7 complexes (46 episodes in 154 h) were detected (Fig. 9).

Thus, the diagnosis of MVP and MAD was confirmed by instrumental methods of examination. No indications for surgical intervention were revealed at this stage. Ventricular arrhythmias requiring medical correction were registered. At the previous treatment stage, beta-blocker monotherapy (2.5 mg/day bisoprolol) was ineffective. Therefore, combined
Antiarrhythmic therapy was decided. Slow-release metoprolol succinate was recommended at a starting dose of 25 mg once daily in the morning, followed by dose titration, if necessary, in combination with 25 mg allafort in the evening. During therapy, repeated 24-h ECG monitoring revealed no runs of nonsustained ventricular tachycardia and registered a significant decrease of number of PVCs from 8,520 in 24 h to 5,000 in 24 h. The patient is still being followed up.

DISCUSSION

Given the correlation of MAD with the severity of MVP and mitral insufficiency and the association with life-threatening ventricular arrhythmias, prompt diagnosis of this pathological condition and dynamic monitoring of patients is extremely important.

Chakrabarti et al. presented a generalized scheme of examination of patients with MVP [18]. The first steps are detailed history taking, including family history of fatal ventricular arrhythmias and sudden death, physical examination with assessment of systolic click and severity of systolic murmur, and resting ECG and EchoCG with targeted MAD searches. EchoCG is the most significant and accessible method for diagnosing changes in valvular apparatus and LV contractile function. However, it has several limitations, i.e., the need for a good acoustic window, limited possibilities for assessing the myocardial structure, and operator dependence. In patients with a high risk of poor prognosis (arrhythmias, MAD on EchoCG findings, and family history of sudden death), CMR is recommended to clarify the presence of MAD and its severity and assess fibrotic changes in the LV myocardium and papillary muscles as additional risk factors. The longitudinal distance of disjunction may vary from 1 to 15 mm around the mitral valve annulus in the same patient, and its severity is most frequently associated with the severity of mitral valve changes [19]. In addition, disjunction may occur in patients without MVP. Marra et al. revealed that abnormal morphology and pathology of mechanical movement of the mitral valve and annulus in MVP may lead to fibrous changes of the LV walls in MVP [9]. CMR allows accurate assessment of the motion of the mitral annulus, adjacent myocardium and inferior or anterior systolic curling at the level of the posterior leaflet. An systolic curling defined by the authors as exceeding the median value of 3.5 mm is associated with a higher frequency and greater volume of areas LGE (fibrosis). Furthermore, a linear correlation was found between the disjunction extent and the severity of systolic motion [9]. Intramural areas of LGE in the inferior basal regions of the LV wall were observed in 72% of patients with MAD and systolic curling. A positive linear correlation between MAD length and degree of fibrosis was detected. Marra et al. reported that the median long axis MAD extent in patients with MVP was 4.8 mm with myocardial fibrosis and 1.8 mm without fibrosis [9]. CMR allows the detection of both local fibrosis and diffuse (interstitial) myocardial fibrosis. Currently, only a few studies have focused on the assessment of diffuse fibrosis in patients with MVP. In 2021, a retrospective description of the results of CMR in 30 patients with MVP combined with MAD was published; the comparison group included patients with mitral regurgitation without MAD and those with normal CMR characteristics [20]. Areas of LGE corresponding to fibrosis were observed in 47% of the patients with MVP-MAD and were absent in all control groups. By using T1 mapping after contrast agent injection, the extracellular volume (ECV) was calculated, which reflected the size of the extracellular space in the myocardium. Increase of ECV may indicate diffuse myocardial fibrosis. In the study, the ECV was higher in MVP-MAD, even in the absence of delayed accumulation of contrast. Remarkably, ECV values were increased in all basal segments of the myocardium, demonstrating fibrous remodeling not limited to the inferior and inferolateral segments in the area of prolapsing leaflet attachment.
Compared with LGE, the ECV of LV basal segments had a stronger association with MAD severity and a similar association with the frequency of sudden cardiac death. The MAD length also correlated with ECV, but not with the extent of LGE. Complex ventricular arrhythmias PVCs and nonsustained ventricular tachycardias were observed in 87% of patients with MVP-MAD. In these patients, ECV exceeded the threshold level, whereas only 53% had areas of LGE.

The presence and severity of systolic curling and mitral valve changes (prolapse and regurgitation) are associated with basal segment hypertrophy in patients with MVP [9]. Basal hypertrophy may have local or concentric distribution. More frequently, the phenomenon of “ballerina’s foot” is observed, i.e., hypertrophy of the basal segments with systolic bulging of the LV anterior wall [9]. Probably, local hypertrophy contributes to arrhythmogenesis in MVP-MAD.

In patients with clinical signs of arrhythmia, 24-h ECG monitoring is indicated. In addition, electrophysiological examination may be performed in patients with a high clinical risk and history of ventricular arrhythmias in the presence of structural changes on CMR. However, CMR and electrophysiological examination are not recommended for all patients. In our case, CMR was indicated to verify the diagnosis of MAD and confirm or exclude fibrotic changes in the myocardium to stratify the risk of fatal ventricular arrhythmias due to nonsustained ventricular tachycardias recorded during ECG monitoring. Since CMR revealed no fibrotic changes in the patient and due to the absence of family history of sudden death, electrophysiological examination was not performed.

The majority of authors agree that the combination of MVP, MAD (irrespective of its extent), and myocardial fibrosis of the LV free wall is a “fatal triad,” which determines the high frequency of ventricular arrhythmias and is accompanied by a high risk of sudden cardiac death [9, 21–23].

In 2020, Han et al. presented the results of a histological analysis of myocardial fibrotic changes in patients with sudden cardiac death and MVP other cardiac causes of death were excluded in comparison with the group of noncardiac deaths [24]. In sudden cardiac deaths combined with MVP, fibrous changes in the LV wall were significantly more frequently observed in the lateral and posterior walls than in the anterior wall and interventricular septum. The authors separately noted a predominantly endocardial–epicardial gradient of increasing fibrotic changes [24].

Currently, our patient has two components of the “fatal triad” (MVP and MAD), and no myocardial fibrotic changes were found in the CMR. Therefore, a decision was made to treat the patient conservatively. However, considering the severity of MAD and structural changes of the mitral valve leaflets and systolic curling of the basal parts of the LV myocardium in the area of MAD, the case belongs to the high risk category of fibrosis development in the future. Therefore, the patient needs follow-up, regular EchoCG monitoring at least once a year, and multi-day ECG monitoring at least once every 6 months. The decision to repeat the CMR is dependent on the results of the monitoring. If the disease progresses, mitral valve surgery and/or implantation of a cardioverter-defibrillator may be required.

CONCLUSIONS

MVP combined with MAD and myocardial fibrosis is a pathological condition predisposing to life-threatening ventricular arrhythmias and sudden death. Given the high frequency of MAD in patients with MVP, a targeted search for disjunction should be performed during EchoCG. If detected, the patient should be referred for CMR to confirm the diagnosis and diagnostically search for fibrosis, which is an additional marker of poor prognosis.

ADDITIONAL INFORMATION

Conflict of interest. There is no conflict of interest.

Consent and anonymity of the patient. The patient provided consent for anonymous use and publication of his medical data.

Competing interests. The authors declare that they have no competing interests.

Funding source. This study was not supported by any external sources of funding.

REFERENCES


Список литературы


AUTHORS INFO

*Tatyana N. Novikova, docent; e-mail: novikova-tn@mail.ru; ORCID: 0000-0003-4655-0297; eLibrary SPIN: 3401-0329

Veronika A. Basova, Cand. of Sci. (Med.), Associate Professor; e-mail: Chudovskaya@hotmail.com; eLibrary SPIN: 3202-6874 ORCID: 0000-0001-5639-1635

Larisa S. Evdokimova, radiologist; e-mail: Larisa.Evdokimova@szgmu.ru; eLibrary SPIN: 3780-9470; ORCID: 0000-0002-7731-0109

Natalia A. Gnevashcheva, Cand. of Sci. (Med.), Associate Professor; e-mail: natasha-line@yandex.ru; ORCID: 0000-0003-4798-533X

* Corresponding author / Автор, ответственный за переписку

ИНФОРМАЦИЯ ОБ АВТОРАХ

*Татьяна Николаевна Новикова, доцент; e-mail: novikova-tn@mail.ru; ORCID: 0000-0003-4655-0297; eLibrary SPIN: 3401-0329

Вероника Анатольевна Басова, канд. мед. наук, доцент; e-mail: Chudovskaya@hotmail.com; eLibrary SPIN: 3202-6874 ORCID: 0000-0001-5639-1635

Лариса Сергеевна Евдокимова, врач-рентгенолог; e-mail: Larisa.Evdokimova@szgmu.ru; eLibrary SPIN: 3780-9470 ORCID: 0000-0002-7731-0109

Наталья Анатольевна Гневашева, канд. мед. наук, доцент; e-mail: natasha-line@yandex.ru; ORCID: 0000-0003-4798-533X

DOI: https://doi.org/10.17816/cardar109160